The pathophysiology of antibody-mediated rejection (AMR) in solid organ transplants is multifaceted and predominantly caused by antibodies directed against polymorphic donor human leukocyte antigens (HLAs). Despite the clearly detrimental impact of HLA antibodies (HLA-Abs) on graft function and survival, the prevention, diagnosis, and treatment of AMR remain a challenge. The histological manifestations of AMR reflect the signatures of HLA-Ab-triggered injury, specifically endothelial changes, recipient leukocytic infiltrate, and complement deposition. We review the interconnected mechanisms of HLA-Ab-mediated injury that might synergize in a 'perfect storm' of inflammation. Characterization of antibody features that are critical for effector functions may help to identify HLA-Abs that are more likely to cause rejection. We also highlight recent advances that may pave the way for new, more effective therapies.
Rejection of solid organ transplants challenges longterm allograft survival
Organ failure is an immense human and economic burden that can be successfully reversed with transplantation, substantially improving quality of life and life expectancy. In the USA, more than 100 000 patients currently await transplantation of major solid organs. Significant advances in histocompatibility and immunosuppression have dramatically improved short-term graft and patient survival rates. Recipient recognition of donor HLA (see Glossary) present in the allograft induces an allogeneic immune response resulting in the production of donor-specific HLA-Abs (DSAs). These antibodies, through many different effector functions, are responsible for the damage, and ultimately graft rejection, that occurs in AMR. AMR has emerged as a leading cause of graft dysfunction and reduced outcomes but is often unresponsive to current therapies [1] . Histological markers of AMR are frequently unreliable and it is controversial whether intervention is required for patients with DSAs but no graft dysfunction. Clinical evidence suggests that DSAs alone, in the absence of histological or molecular evidence of antibody-mediated injury, is not detrimental to renal allograft survival [2, 3] . However, long-term follow-up studies of asymptomatic or subclinical AMR in cardiac [4, 5] and renal [6] transplantation have demonstrated increased risk for chronic rejection. Consequently, AMR remains a diagnostic and therapeutic challenge. Here we highlight recent developments in our understanding of how HLA-Abs function to cause graft injury, emphasizing the multiple effector mechanisms of HLA-Abs, specifically IgG, and how they relate to the risk for and manifestations of AMR.
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Glossary
Acute rejection: commonly refers to rejection that arises rapidly and causes graft dysfunction within days to weeks, often occurring in the early posttransplantation period (less than 1 year). May be mediated primarily by T cells [TCMR or acute cellular rejection (ACR)] or primarily by antibodies (humoral rejection or AMR) and can often be reversed with aggressive treatment. Allograft: transplanted cells or solid organ from a genetically disparate member of the same species. Alloimmunity: adaptive immune responses against non-self cells or tissue from members of the same species as a result of polymorphisms in proteins that are then recognized as foreign antigens. Chronic rejection: also called transplant allograft vasculopathy (TAV), transplant arteriopathy, or transplant arteriosclerosis (TA) in cardiac allografts, transplant glomerulopathy (TG) in renal allografts, bronchiolitis obliterans syndrome (BOS) in lung allografts, and vanishing bile duct syndrome in liver allografts. Progressive and irreversible fibrosis and occlusion of the donor vasculature, distinct from native atherosclerosis in that it is concentric rather than focal and affects only the vessels of the allograft. Thought to result from repair mechanisms in response to successive insults or indolent, ongoing injury from antibodies and/or CD4 T cells; manifests as an expanded subendothelial layer comprising ECs and smooth muscle cells that have migrated and proliferated in the neointima, as well as CD4 T cells and macrophages. Classical complement pathway: a system of proteases that consecutively cleave downstream components to generate catalytically active or inflammatory and cytolytic products. The classical pathway is activated by immunoglobulin and initiated by binding of C1 complex to the Fc region of IgM or IgG. Donor-specific HLA-Abs (DSAs): antibodies directed against polymorphic HLA molecules expressed by donor tissue. Fc receptors: receptors for the crystallizable fragment (Fc) of immunoglobulin, expressed by myeloid and some lymphoid cells. Link the innate immune system with adaptive immunity; binding to complexed or immobilized antibody triggers intracellular signaling leading to activation and inflammatory effector functions. Human leukocyte antigen (HLA): genes encoded by the MHC. These proteins function in antigen presentation of peptides to T cells and are the most polymorphic loci in the human genome. Transplant rejection: alloimmune response of the recipient against transplanted donor cells, tissues, or organs.
The alloimmune response Immunity to alloantigens is surprisingly robust, mediated by MHC molecules, and based on exposure to allogeneic tissues. The MHC locus covers almost 4000 kb on human chromosome 6 and is polygenic, containing three loci of HLA class I (HLA-A, -B, and -C) and six to nine functional HLA class II loci (a and b chains of HLA-DR, -DP, and -DQ), as well as many nonclassical MHC, minor histocompatibility antigen, and immune-related genes. Balancing selection has resulted in extreme polymorphism within HLA class I and class II genes. To date, over 10 000 nucleotide sequences encoding more than 6000 class I and 2000 class II unique proteins have been reported [7] . The high allelic diversity of MHC genes is advantageous for protection of populations against pathogens but is highly unfavorable for cell and organ transplantation.
Immune sensitization to HLA occurs after exposure to allogeneic tissue through pregnancy, transfusion, or transplantation. Twenty percent of healthy individuals [8, 9] and up to 30% of transplantation candidates have HLA-Abs. Another 8-25% of recipients develop de novo DSAs after receiving a graft [10] [11] [12] . Half of pre-sensitized patients and a third of patients with de novo DSAs will experience AMR within the first year after transplantation [10, 12] . Antibody responses against donor HLA proteins are not well controlled by current immunosuppression regimens [1] . Therefore, AMR can occur at any time and is a common occurrence more than 1 year post-transplantation [13] . DSAs and subsequent rejection episodes are strongly associated with risk of chronic rejection and late graft failure [13] [14] [15] .
Histological manifestations and diagnostic criteria of AMR AMR is best defined in renal [16] , cardiac [17] , and pancreas [18] transplantation, although the diagnostic histological criteria for AMR differ somewhat from organ to organ. Central features include endothelial cell (EC) swelling, microvascular inflammation (subendothelial mononuclear cell infiltration), and intravascular CD68 + macrophages, with or without complement C4d deposition, often in the presence of circulating DSAs (Figure 1 ) [17, 19, 20] . While HLA-Abs are detrimental to liver [21] , lung [22] , and small bowel [23] allograft survival, clear pathological definitions of AMR remain contentious [17] , as the utility of C4d and other histological markers remains unclear in these tissues.
The donor vasculature present at the interface between donor tissue and the recipient immune system is the primary target of the alloimmune response. AMR is increasingly viewed as predominant endothelial injury and vascular inflammation [24, 25] and the principal involvement of the endothelium in AMR has been revealed by gene-profiling studies of renal biopsies undergoing AMR [2, 3, 26] .
HLA-Abs and subclass biology
The fact that some patients with DSAs do not experience AMR suggests that other factors influence susceptibility or risk of rejection in the presence of antibodies that bind the graft. The histological manifestations of AMR reflect the injurious functions of HLA-Ab binding to the vasculature, causing endothelial signaling and inflammation, activation of the classical complement cascade, and recruitment of effector cells. IgG is the most common isotype of circulating immunoglobulin and is divided into four subclasses with unique patterns of biological activity. IgG3 is the strongest activator of complement, followed closely by IgG1, and, to a far lesser extent, by IgG2 [27] . IgG4 has no detectable complement activity and is often linked with IgG2 as 'non-complement fixing'. However, it should be noted that, under unique conditions such as high antigen/ epitope density or increased concentrations of complement and IgG [28, 29] , all subclasses, including IgG2 and IgG4, effectively activate complement. In addition, work with murine MHC antibodies has demonstrated synergism between high-and low-complement-fixing IgG subclasses [30] [31] [32] . While this has not yet been explored using human IgG and complement, it is pertinent given that most antibody responses are polyclonal and HLA is often recognized by an admixture of subclasses. IgG subclass interaction with Fc receptors (FcgRs) is more complex (Table 1 ). In general, IgG3 and IgG1 have the highest affinity for most FcgRs, while IgG2 and IgG4 are bound by a more restricted repertoire of FcgRs. Unfortunately the disparity between murine and human immunoglobulin systems limits the translation of in vivo mechanistic studies of IgG subclass effector functions in murine models of AMR to human disease [33] .
After transplantation, IgG1 antibodies are directed against approximately 90% of HLA specificities whereas those of IgG2/3/4 recognize about 40% or less [34] [35] [36] . These results indicate a polyclonal response wherein each donor HLA antigen is recognized by multiple subclasses, most commonly including IgG1. It has been difficult to reconcile the apparently conflicting results regarding the association of DSA subclass and clinical outcome, despite reports of IgG1/3 dominating the alloantibody responses [37] . IgG3 DSAs were associated with increased risk of allograft loss in liver [35] and renal [38] transplantation. By contrast, others have reported no correlation between DSA subclass and risk of AMR or graft loss, although one study found a trend toward lower AMR in patients with only IgG2/4 DSAs [39] .
HLA-Abs and complement activation
The historical paradigm of AMR was one of complementmediated damage caused by classical pathway activation by Fc regions of DSAs bound to the allograft [30] . In recent years, complement-fixing DSAs have become a controversial topic. C4d-negative AMR is becoming increasingly recognized and the diagnostic schemata for heart and renal AMR have been updated to reflect this entity [20] . Experimental mouse models of AMR suggest that acute rejection is dependent on complement fixation [40] . By contrast, intimal thickening during antibody-induced chronic rejection occurred in complement-deficient murine recipients, suggesting that there was no requirement for complement in this process [41] . Importantly, local production of complement by donor ECs could not be excluded [42] . These results from animal models are consistent with clinical observations that terminal complement inhibitors could not prevent chronic rejection [43, 44] . Furthermore, studies using methods to define DSAs that are complement fixing, and determine whether complement fixation translates to graft damage, have had conflicting results [45] [46] [47] [48] [49] .
Of the three complement pathways [50] , the classical pathway is primarily responsible for DSA-mediated complement activation. Early activation results in the production of soluble mediators such as the anaphylatoxins C3a and C5a, which are potent chemoattractants for leukocytes and alter the microvasculature by increasing vascular permeability and inducing expression of adhesion molecules. The later stages are characterized by membrane attack complex (MAC) formation, which causes osmotic lysis of the target. Given the general resistance of ECs to complement-mediated lysis due to high expression of complement regulatory proteins, the physiological relevance of lytic terminal MAC formation during rejection is unclear [30] . Early complement proteins, rather than terminal MAC formation, are likely to be the mediators of most complement-associated damage to the graft ( Figure 2A ).
Factors that dictate complement activation
Many components modulate complement fixation by IgG. Of these, three are intrinsic to the antibody itself: IgG subclass, glycosylation, and affinity ( Figure 2B ,C). Multiple studies have defined the importance of antibody affinity in dictating the level of complement activation [51] . Repeated injury and consistent antigen exposure may increase the affinity of DSAs over time, resulting in HLA-Abs that are more inflammatory and cause robust complement induction.
Additionally, extrinsic factors such as antigen density/ epitopes and complement concentration also regulate antibody-induced complement activation [52] . Despite constitutive allograft endothelium expression of HLA class I and II [53] , these levels are altered in response to inflammatory cues [54] . Many in vitro studies have shown that increased alloantibody bound to cells resulted in enhanced complement deposition, and this was augmented under inflammatory conditions [55, 56] . Moreover, binding of multiple antibodies with distinct epitopes to a single HLA molecule synergistically enhanced complement activation [36] . If antibody subclass and antigen density/epitopes coordinate to determine complement activation by DSAs, polyclonal antibodies should elicit more complement activation than monoclonal antibodies. Sera with >80% panel reactive antibody (PRA) are strong inducers of complement activation [55, 56] , supporting the notion that differing levels of HLA antigen/ epitopes determine both the quantity and quality of DSAs bound to the graft ( Figure 2D ).
Lastly, variations in complement can determine the degree of activation, as some complement proteins are located in the MHC locus (C2, C4) and are also polymorphic [57] . Genetic predisposition to specific polymorphisms may be useful for risk stratifying patients, and polymorphisms in complement C4 [58] but not C3 [59] have been shown to influence renal allograft outcome. In addition, complement concentration is potentiated in response to local inflammation. Renal epithelium, macrophages, cardiocytes, and vascular endothelium [42] are sources of extrahepatic complement production during episodes of rejection. As low-lytic antibodies have enhanced activity when complement is elevated, and IgG4 activates complement when antigen density and complement levels are increased [28] , patients with minimal complement-fixing DSAs may have a higher degree of damage during rejection episodes, when complement and antigens are more abundant.
Measuring DSA-induced complement activation Complement activation by DSAs is a highly dynamic process responsible for mediating damage to the allograft; therefore, clinical assays that discern the complementfixing potential of DSAs are in high demand. The lymphocytotoxicity cross-match (CDC-XM) assay developed by McClelland and Terasaki [60] was established for highly sensitive detection of DSAs to recipient HLAs. Although this assay utilizes complement fixation as a read-out, it is not fully reflective of the potential physiological capacity of DSAs to activate human complement due to the use of rabbit serum as a source of complement. It should also be noted that human IgG2 is highly effective in the activation of rabbit complement [61] ; consequently, DSA subclass and CDC-XM results may not always correlate.
The development of high-throughput, single-antigen, bead-based assays has been an important tool for risk stratifying patients with complement-fixing DSAs [45, 62, 63] . Specifically, the C1q assay measures HLA-Abs that bind C1q and, although informative, recognizes binding only, not physiological complement activation [62] . Recently, a new assay measuring DSA-induced complement deposition (C3d) reported that C3d + DSAs were significant predictors of allograft loss [64] . Collectively, these in vitro diagnostics attempt to measure the pathogenicity of HLAAbs with regard to their complement-fixing potential. However, results differ regarding the predictive value of detecting complement-fixing HLA-Abs in vitro with respect to clinical outcomes [39, 45, 49, 62, [65] [66] [67] , and new diagnostic criteria for AMR include rejection without histological evidence of complement activation (C4d deposition) [17, 20, 68] .
HLA-Abs and FcgRs
An almost universal histological feature of AMR is the infiltration of CD68 + macrophages in the microvascular and perivascular spaces of heart and renal allografts [17, 19, 69, 70] and neutrophils in lung transplants [22] , which is predictive of worse outcome [69] . In addition, gene-expression profiling studies have uncovered a natural killer (NK) cell signature during AMR [2,71,72], findings Review 5 that were paralleled by experimental animal models of AMR implicating NK cells in chronic antibody-mediated rejection [73] . Monocytes, macrophages, neutrophils, and NK cells express receptors for the Fc region of antibodies (Table 1 ) [74] and FcgRs mediate innate immune cell functions such as leukocyte recruitment, cytotoxicity, and phagocytosis that are highly relevant to the etiology of AMR (Figure 3 ).
FcgR families and alleles
FcgR families and alleles have distinct subclass specificities and divergent activities (Table 1) [33, 75] . Moreover, functional polymorphic variants of FcgRIIa (H131R), FcgRIIIa (F158V), and FcgRIIIb (NA1/NA2 alleles) are associated with differential phenotypes in response to antibody-based antitumor therapies, susceptibility to infection, and risk of autoimmune disease [76] . In the context of transplantation, the low-affinity FcgRIIa-R131 allele was associated with increased risk of acute T cell-mediated rejection (TCMR) [77] , but this is likely a reflection of reduced responsiveness to antibody-based leukocyte depletion induction regimens rather than predisposition to rejection per se. However, the effect of transplant recipient FcgR polymorphism on risk of AMR has not yet been studied and warrants investigation. As with IgG subclasses, the human FcgR system is dissimilar from the murine system, complicating the study of FcgRs in vivo and confounding the translation of experimental results in murine models of AMR to the human setting. A recently described novel transgenic mouse carrying the full repertoire of human FcgRs [78] may enable future studies. Several important caveats, however, including cross-reactivity of human FcgRs with endogenous murine IgG and the representation of only one FcgR genotype, may limit findings [33] .
FcgR functions relevant to graft injury
FcgRs on monocytes, macrophages, and NK cells facilitate antibody-dependent cell-mediated cytotoxicity (ADCC). While HLA-Abs trigger NK cell degranulation and cytotoxicity against allogeneic target cells in vitro [79] , and macrophages also perform ADCC, currently there is no direct evidence that these cells cause cytotoxicity in the graft. However, murine models of chronic AMR have revealed a novel role for NK cells in MHC antibody-induced transplant vasculopathy [73] , through undefined FcgRdependent mechanisms. An elegant study imaging the trafficking of recipient immune cells into murine cardiac allografts revealed elevated phagocytic activity during rejection, mediated by recipient macrophages [80] . HLAAbs may provoke antibody-dependent cellular phagocytosis (ADCP) by macrophages and neutrophils, contributing to enhanced presentation of alloantigen to T cells, but the pathophysiological relevance of phagocytosis during rejection remains to be explored.
Finally, FcgRs are involved in the capture of leukocytes by immune complexes (ICs) and monomeric anti-endothelial cell antibodies, and enhanced trafficking of neutrophils to inflamed endothelium in autoimmune settings [81] . It is notable that there was a prerequisite for tumor necrosis factor alpha (TNFa) activation of endothelium, as deposition of antibody on resting cells did not cause efficient neutrophil adhesion. Moreover, concurrent expression of chemokines was required for efficient neutrophil adhesion to ECs coated with monomeric IgG but not with ICs. It was recently demonstrated that monocyte recruitment to HLAAb-activated endothelium was augmented by the interaction of monocyte FcgRs with the Fc portion of the HLA-Abs [82, 83] . This interaction was subclass dependent, influenced by monocyte FcgRIIa allelic variants, and abrogated by enzymatic modulation of antibody Fc regions using EndoS or IdeS [83] . In contrast to reports using murine anti-endothelial cell antibodies [81] , efficient recruitment was observed using HLA-Abs without pre-activating ECs with inflammatory cytokines, and it has been hypothesized that HLA-Abs are unique in their capacity to trigger direct endothelial activation and expression of selectins as well as stimulate FcgRs [82] . Interestingly, monocytes from donors who expressed the high-affinity FcgRIIa-H131 allele exhibited significantly greater FcgR-dependent adhesion to ECs activated with HLA-Abs of both IgG1 and IgG2 subclasses compared with monocytes expressing only FcgRIIa-R131. These results suggest that transplant recipients carrying high-affinity FcgR alleles may experience exacerbated leukocyte infiltration in response to HLA-Abs, predisposing them to AMR.
HLA-Abs and glycosylation
Patterns of antibody glycosylation strongly influence affinity of FcgRs [84] . The bulk of evidence comes from the fields of tumor immunology and recombinant therapeutic antibodies, through glycoengineering of antibodies to alter ADCC and complement-dependent cytotoxicity (CDC) properties. In addition, several studies have correlated the degree of IgG-Fc glycosylation with the severity of antibody-mediated disease [85] . A common theme appears: antibodies with agalactosylated Fc-glycans are more proinflammatory than those containing glycans with terminal galactosylation or sialic acid. As the properties of glycosylation moieties modulate the inflammatory nature of IgG, the Fc-glycan may participate in determining the degree of pathogenicity of DSAs with respect to AMR.
The conserved yet highly heterogeneous N297 glycan present on the Fc of all IgGs [27, 86] contains a biantennary core heptasaccharide that is further modified by the addition of fucose (over 90% of IgGs), galactose, and sialic acid to greatly diversify the IgG glycoform pool. Various changes to this structure can completely alter the function of IgG with respect to both FcgR and complement-dependent activities (reviewed elsewhere [27, 87] ). In brief, removal of fucose increases ADCC whereas removal of galactose residues reduces ADCC (mediated by FcgRIIIa) and CDC. Interestingly, sialic acid has been identified as the mediator of the anti-inflammatory properties of intravenous immunoglobulin (IVIg) [84] , a common modality in the treatment of AMR. Whereas all sialic acid linkages contribute to decreased ADCC, the alpha-2,6 version is responsible for the anti-inflammatory effects of sialylated IgG, through direct binding of SIGN-R1/DC-SIGN, causing upregulation of inhibitory FcgRs. Although there is minimal literature regarding differential glycosylation patterns of DSAs, one would be remiss to disregard the potential role of DSA glycan heterogeneity during the course of AMR.
Regulation of IgG glycosylation
Given that both complement activation and FcgR engagement are key effector functions of HLA-Abs in causing allograft injury, the Fc region of the antibody is a potential therapeutic target. The Gram-positive bacterium Streptococcus pyogenes expresses a battery of immunomodulatory enzymes that aid in its pathogenicity, two of which have shown promise in preclinical autoimmune models through specific actions on IgG [88] . The peptidase IdeS cleaves off the Fc fragment of human IgG, generating a F(ab') 2 fragment, while the endoglycosidase EndoS hydrolyzes the N297-linked Fc glycan. Both ameliorate inflammation, complement activation, and FcgR-dependent leukocyte recruitment in several experimental models and treatment of HLA-Abs with either EndoS or IdeS dramatically reduced the recruitment of monocytes to ECs [83] . Clinical trials are currently under way testing the efficacy of IdeS in sensitized kidney transplant recipients (NCT02224820).
Glycan analysis of antibodies produced during inflammation in response to pathogens or autoimmune disease have shown an increased proportion of agalactosylated IgG. Moreover, IgGs from active immune responses have altered glycan profiles that differ from normal serum IgGs [89, 90] . The mechanism by which antibodies are glycosylated during immune responses is not well understood, although distinct glycan profiles from individual patients suggest differential glycosylation by unique B cell subsets [91, 92] . This indicates that the ability to regulate levels of glycosylation relies on B cell-intrinsic factors and would be subject to the immune milieu. In this regard, B cells presented with T-dependent antigens under proinflammatory conditions produced antibody that lacked galactose (proinflammatory) [89, 93] , whereas antibodies produced in response to T-dependent antigens but under tolerogenic settings were heavily sialylated (anti-inflammatory) [89] . Finally, in the context of T-independent antigens, regardless of the inflammatory surroundings IgGs were sialylated and immunosuppressive [93] .
This comprehensive understanding of the contribution of Fc-glycan to the immune function of IgG and the circumstances modulating the production of these glycosylated antibodies allows conjecture regarding the pathogenic potential of DSAs. One could surmise that acute rejection episodes increase levels of agalactosylated DSAs, which would incur damage to the graft through both complement and FcgR pathways, whereas DSAs present in accommodated grafts may be heavily sialylated and somewhat tolerogenic. Future work detailing the glycan profiles of DSAs would determine whether antibody glycosylation status correlates with the severity of AMR. Additionally, a new methodology described to simultaneously measure both the subclass and glycosylation of antigen-specific IgG [94] may be adapted to transplantation.
HLA-Abs and endothelial activation and regulation of immunogenicity
There has been resurgence in the appreciation of ECs as important regulators of the immune response. ECs can undergo acute (Type I) or chronic (Type II) activation, leading to expression of chemokines and adhesion molecules and recruitment of leukocytes to sites of inflammation [95] . Past work showed that crosslinking of HLA by antibodies triggers intracellular signaling through focal adhesion kinase (FAK), Akt, mammalian target of rapamycin (mTOR), S6 kinase (S6K), S6 ribosomal protein (S6RP), and extracellular signal-regulated kinase (ERK1/2) in endothelial and smooth muscle cells leading to dynamic cytoskeletal reorganization and increased cell proliferation, migration, and survival [96] . Multiple groups recently confirmed the activation of these signaling pathways in biopsies from cardiac allografts undergoing AMR [97, 98] . Importantly, the agonistic signaling capacity is an observed property of all HLA-Abs requiring the bivalent F(ab') 2 region of IgG and does not appear to depend on subclass, complement, or FcgRs. Alternatively, complement activation, antigen expression, epitope density, and antibody affinity will all significantly impact the binding to and crosslinking of HLAs on ECs, in turn affecting intracellular signaling.
Recent studies demonstrated that HLA class I signaling triggers Type I EC activation, resulting in a rapid increase of cell surface P-selectin and the adhesion of neutrophils and monocytes to endothelium [99, 100] . Exocytosed von Willebrand factor (vWF) and P-selectin also facilitated the capture and activation of platelets, which aggregate in the microvasculature and support the tethering of monocytes [101] . Platelets express FcgRIIa [102] ; therefore, additional mechanisms of FcgR-dependent platelet adhesion cannot be excluded. HLA crosslinking also activated the transcription factors cAMP response element-binding protein (CREB) and noncanonical nuclear factor kappa B (NFkB), resulting in increased protein expression of late phase adhesion molecules, cytokines, and chemokines [56, 103] , consistent with Type II EC activation.
An expanding paradigm of the role of vascular endothelium in directly stimulating adaptive immune responses has gained attention [104, 105] . HLA class II-expressing ECs trigger allogeneic CD4 T cell proliferation and promote generation of T helper 17 (Th17) and regulatory T cell (Treg) subsets [106, 107] . Interestingly, rapamycin treatment of ECs resulted in selective expansion of Tregs via programmed death ligand (PD-L) 1 and 2 [107] , indicating a role for mTOR in the regulation of endothelial alloimmunogenicity through modulation of costimulatory molecule expression. The mTOR inhibitors sirolimus and everolimus also prevent HLA I antibody-induced endothelial migration and proliferation [108] , suggesting that rapalogs may be beneficial in preventing multiple manifestations of graft injury by HLA-Abs. A recent study showed HLA-Abs increased expression of proinflammatory cytokines and the activation of noncanonical NF-kB [56] , Figure 4A ). In addition to the direct effects of complement on macrophages, anaphylatoxins and sublytic MAC enhance EC activation. Endothelial NF-kB signaling and inflammatory gene expression induced by DSA binding was augmented in the presence of sublytic MAC and led to increased T cell stimulation [56] . These findings demonstrate an additional mechanism of synergy between complement and HLA-Abs in endothelial activation ( Figure 4B ). As C5a is a potent mediator of leukocyte recruitment as well as a novel modulator of T cell alloimmunity [114] , this DSA-induced inflammatory loop could exacerbate damage during episodes of AMR.
Concluding remarks and future perspectives
In summary, graft injury results from the pleiotropic function of antibodies ( Figure 5 ), through canonical Fc-mediated effector functions as well as novel agonistic actions on HLA molecules. The collective action of antibodies on donor vascular cells, including complement activation, FcgR-dependent macrophage and NK cell functions, and EC activation, are likely to synergize, causing damage to the allograft. Features such as antibody subclass, Fc glycosylation, and FcgR polymorphisms may be key determinants of HLA-Ab pathogenicity and recipient risk of AMR. Therefore, characterization of the patient's DSAs and immune repertoire provides a foundation for individualized medicine as well as possible guidelines for the risk stratification of transplantation patients. Highly tailored and specific immunotherapies could be used in the transplantation field to modulate patient immune responses according to the details of an individual's immune repertoire. Further experimental dissection of alloimmunity variables (Box 1) will guide future practice in allocation/antigen avoidance, management in sensitized patients, and the development of new drugs to prevent and treat AMR. Figure 5 . Mechanisms of donor-specific antibodies (DSAs) in graft pathogenesis. Features of antibody-antigen and antibody-effector system interactions that influence pathogenic functions and mechanisms of injury are shown. Variable factors regulating antibody-antigen interactions (blue ovals) directly influence the capacity of an antibody to trigger effector functions (yellow boxes) and mechanisms causing graft injury (green boxes), which ultimately manifest in the graft as common histological features (red circles). Linear effects are indicated by solid arrows. The functional end points of antibody-mediated injury are interrelated (with potential inflammatory loops indicated by broken arrows) and are likely to synergize to cause maximal inflammation during antibody-mediated rejection (AMR). For example, direct endothelial cell activation by human leukocyte antigen (HLA) antibodies triggers adhesion of leukocytes, which can be enhanced when those leukocytes bind antibody through Fc receptors (FcgRs). Activation of complement at the endothelial cell surface may cause production of the anaphylatoxins C3a and C5a, which can act on leukocytes as chemoattractants, or enhance endothelial activation.
TRENDS in Molecular Medicine
Box 1. Outstanding questions
Which mechanisms of HLA-Abs are critical for rejection and graft injury and how do these mechanisms vary depending on antibody characteristics? What are the effector functions of NK cells during AMR? Do ADCC and ADCP play a mechanistic role in AMR? Can we reliably define the HLA-Ab repertoire, including specificity, glycosylation, complement-fixing capacity and subclass distribution, of transplantation patients? In particular, do current in vitro assays of complement detection reliably predict whether HLA-Abs will cause complement-mediated injury? Are some patients predisposed to experience rejection in the presence of antibodies? Does the glycan profile of DSAs or the recipient FcgR genotype influence transplant outcome? Should patients be treated when they have DSAs but no evidence of graft dysfunction? What is the significance of C4d-negative AMR? Does it represent complement-independent graft injury by non-complement-fixing antibodies or is it capturing AMR after complement is no longer active?
